{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:59Z","timestamp":1791605879500,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM135007"],"award-info":[{"award-number":["P20 GM135007"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005881","name":"Hemostasis and Thrombosis Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:19:03Z","timestamp":1754479143000},"page":"3160-3172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc\u2013Biomarkers model"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3847-4768","authenticated-orcid":false,"given":"Samuel A.P.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Judd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed Z.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Kissela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6143","authenticated-orcid":false,"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.007_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2025.06.007_bib2","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","article-title":"Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis","volume":"126","author":"Reynolds","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.007_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"Lip","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.007_bib7","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib9","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib10","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1093\/eurheartj\/ehw077","article-title":"Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation","volume":"37","author":"Aspberg","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib11","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/STROKEAHA.116.013880","article-title":"Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study","volume":"47","author":"Chao","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib12","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/eurheartj\/ehab059","article-title":"Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function","volume":"42","author":"de Jong","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1161\/CIRCULATIONAHA.120.053100","article-title":"Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation","volume":"143","author":"Benz","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib15","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib17","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","volume":"130","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib18","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1055\/s-0037-1615530","article-title":"D-dimer and factor VIIa in atrial fibrillation\u2014prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy","volume":"115","author":"Siegbahn","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/STROKEAHA.118.024305","article-title":"Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores","volume":"50","author":"Rivera\u2013Caravaca","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07853890.2017.1378429","article-title":"Enhancing the \u201creal world\u201d prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers","volume":"50","author":"Rold\u00e1n","year":"2018","journal-title":"Ann Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020157","article-title":"multiple blood biomarkers and stroke risk in atrial fibrillation: the REGARDS study","volume":"10","author":"Singleton","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.007_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000086678","article-title":"The reasons for geographic and racial differences in stroke study: objectives and design","volume":"25","author":"Howard","year":"2005","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jtha.2025.06.007_bib23","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1161\/STROKEAHA.111.621367","article-title":"Self-reported atrial fibrillation and risk of stroke in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study","volume":"42","author":"Soliman","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s12031-019-01373-1","article-title":"Association between cystatin c and the risk of ischemic stroke: a systematic review and meta-analysis","volume":"69","author":"Wang","year":"2019","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.jtha.2025.06.007_bib25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1160\/TH16-07-0519","article-title":"The REasons for Geographic and Racial Differences in Stroke Study (REGARDS)","volume":"117","author":"Zakai","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1055\/s-0038-1655766","article-title":"Factor VIII, protein C and cardiovascular disease risk: the REasons for Geographic and Racial Differences in Stroke Study (REGARDS)","volume":"118","author":"Zakai","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib27","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ene.13440","article-title":"Galectin-3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort","volume":"24","author":"Arora","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jtha.2025.06.007_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194153","article-title":"Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: the Reasons for Geographic and Racial Differences in Stroke cohort","volume":"13","author":"Alexander","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtha.2025.06.007_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022601","article-title":"Growth differentiation factor-15 predicts death and stroke event in outpatients with cardiovascular risk factors: the J-HOP study","volume":"10","author":"Negishi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.007_bib30","doi-asserted-by":"crossref","first-page":"e2375","DOI":"10.1212\/WNL.0000000000007416","article-title":"Inflammatory cytokines and ischemic stroke risk: the REGARDS cohort","volume":"92","author":"Jenny","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jtha.2025.06.007_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS Study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2025.06.007_bib32","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1161\/STROKEAHA.114.004712","article-title":"N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort","volume":"45","author":"Cushman","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib34","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/sim.5727","article-title":"Testing for improvement in prediction model performance","volume":"32","author":"Pepe","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference: understanding AIC and BIC in model selection","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociol Methods Res"},{"key":"10.1016\/j.jtha.2025.06.007_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bimj.201200045","article-title":"Review and comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring","volume":"55","author":"Blanche","year":"2013","journal-title":"Biom J"},{"key":"10.1016\/j.jtha.2025.06.007_bib38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib39","article-title":"Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies","volume":"352","author":"Emdin","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.06.007_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjcard.2017.09.033","article-title":"Usefulness of the American Heart Association\u2019s Life Simple 7 to predict the risk of atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke [REGARDS] Study)","volume":"121","author":"Garg","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib43","author":"Therneau"},{"key":"10.1016\/j.jtha.2025.06.007_bib44","author":"Harrell"},{"key":"10.1016\/j.jtha.2025.06.007_bib45","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib46","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1373\/clinchem.2009.128397","article-title":"Cystatin C and cardiovascular risk","volume":"55","author":"Taglieri","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2025.06.007_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cardfail.2006.07.005","article-title":"Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul study","volume":"12","author":"Ix","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.jtha.2025.06.007_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/HJH.0000000000000757","article-title":"Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism","volume":"34","author":"Huerta","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.jtha.2025.06.007_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jacc.2003.11.062","article-title":"Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation","volume":"43","author":"Conway","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib50","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1055\/s-0038-1650653","article-title":"Interleukin-6 stimulates coagulation, not fibrinolysis, in humans","volume":"76","author":"Stouthard","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib51","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1002\/ehf2.13445","article-title":"Temporal change in inflammatory biomarkers and risk of cardiovascular events: the Multi-ethnic Study of Atherosclerosis","volume":"8","author":"Shabani","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jtha.2025.06.007_bib52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2025.06.007_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2025.06.007_bib54","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.007_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations Between Lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib56","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007372","article-title":"Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (Atherosclerosis Risk in Communities) study","volume":"6","author":"Aronis","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.007_bib57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0002-8703(98)70151-6","article-title":"Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: A transesophageal echocardiographic study","volume":"136","author":"Igarashi","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2025.06.007_bib58","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.65.1.2","article-title":"MIC-1 is a novel TGF-\u03b2 superfamily cytokine associated with macrophage activation","volume":"65","author":"Fairlie","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jtha.2025.06.007_bib59","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/MCB.20.10.3742-3751.2000","article-title":"Characterization of growth-differentiation factor 15, a transforming growth factor \u03b2 superfamily member induced following liver injury","volume":"20","author":"Hsiao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jtha.2025.06.007_bib60","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2025.06.007_bib61","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.007_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jth.12100","article-title":"GDF-15 prevents platelet integrin activation and thrombus formation","volume":"11","author":"Rossaint","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/clc.22844","article-title":"Growth differentiation factor 15 is associated with left atrial\/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation","volume":"41","author":"Hu","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2020.01.022","article-title":"GDF-15 is associated with thrombus burden in patients with deep venous thrombosis","volume":"187","author":"Liang","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.007_bib66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/circ.149.suppl_1.54","article-title":"Circulating biomarkers and ischemic stroke risk in adults with atrial fibrillation taking anticoagulation: the REGARDS Study","volume":"149","author":"Short","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.007_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078797","article-title":"GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men","volume":"8","author":"Wallentin","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jtha.2025.06.007_bib68","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029110","article-title":"NT-proBNP and all-cause and cardiovascular mortality in US adults: a prospective cohort study","volume":"12","author":"Echouffo\u2013Tcheugui","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.007_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001794","article-title":"CHA2DS2-VASc score stratifies mortality risk in patients with and without atrial fibrillation","volume":"8","author":"Harb","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.jtha.2025.06.007_bib70","first-page":"1385","article-title":"ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2025.06.007_bib71","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.06.007_bib72","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation","volume":"69","author":"Marzec","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib73","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2025.06.007_bib74","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jth.12638","article-title":"D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation\u2014observations from the ARISTOTLE trial","volume":"12","author":"Christersson","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.007_bib75","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1161\/STROKEAHA.115.010947","article-title":"Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation","volume":"46","author":"Takabayashi","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib76","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","author":"Banerjee","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2025.06.007_bib77","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1161\/01.STR.0000185927.63746.23","article-title":"Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study","volume":"36","author":"Miyasaka","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2025.06.007_bib78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jcpt.12481","article-title":"Dawn of the direct-acting oral anticoagulants: trends in oral anticoagulant prescribing in Wales 2009\u20132015","volume":"42","author":"Protty","year":"2017","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jtha.2025.06.007_bib79","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.9778\/cmajo.20130032","article-title":"Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis","volume":"1","author":"Xu","year":"2013","journal-title":"CMAJ Open"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:24:10Z","timestamp":1790817850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625003903"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.007","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc\u2013Biomarkers model","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.05.029","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}